Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITHACA: Peritumoral Immunotherapy in Early-Stage Cervical Cancer
NCT06095674Phase 1Not yet recruiting
- Sponsor
- University of Amsterdam
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balstilimab and botensilimab in Cervical Cancer (CC), sponsored by University of Amsterdam. Primary endpoint: Dose Limiting Toxicity at 2 years. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
balstilimabbotensilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06095674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095674.